Single port robotic colorectal surgical procedure for Anus Prolapse

Phase-Based Progress Estimates
Anus Prolapse+4 More
Single port robotic colorectal surgical procedure - Device
All Sexes
What conditions do you have?

Study Summary

This trial will test whether a robotically-assisted surgery platform, currently used for colorectal surgery indications, is safe and effective for use in head and neck surgery.

Eligible Conditions
  • Anus Prolapse
  • Colorectal Carcinoma
  • Stoma Colostomy
  • Colorectal Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 30 days

30 days
Assess safety & quality event rate for SP platform transabdominal and transanal colorectal operations

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Single Port Robotic Surgery Arm
1 of 1

Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: Single port robotic colorectal surgical procedure · No Placebo Group · N/A

Single Port Robotic Surgery Arm
Experimental Group · 1 Intervention: Single port robotic colorectal surgical procedure · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30 days

Who is running the clinical trial?

Ankit Sarin, MD, MHALead Sponsor
Ankit Sarin, MDPrincipal InvestigatorUniversity of California, San Francisco

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a colorectal diagnosis requiring operative interventions
Patients who would meet standard guidelines for a transanal procedures (T1N0 rectal adenocarcinoma, Precancerous adenomas, and localized neuroendocrine tumors) distal to 15 cm from the anal verge.
You agree to comply with the requirements of the protocol and complete study measures.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: November 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
How old are they?
18 - 6550.0%
What site did they apply to?
UCSF Medical Center at Mission Bay100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%